ProCE Banner Activity

SIMPL’HIV Wk 144 Results: Dolutegravir + Emtricitabine vs Standard Combination ART for Maintenance of Virologic Suppression

Slideset Download
Conference Coverage
Switching from standard combination ART to DTG plus FTC was noninferior to continuing standard combination ART in virologically suppressed adults through Week 144 in this randomized clinical trial.

Released: August 02, 2022

Expiration: August 01, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner